SyntheX is using the power of genetics and synthetic biology to build the next generation of drug discovery engines. 

We create cell-based platforms to produce and functionally select molecules to target conventionally 'undruggable' proteins.

OUR TECHNOLOGY

Using genetically engineered circuits, our platform technologies rely on functional intracellular drug selection as opposed to in vitro screening. This allows us to discover compounds with novel modes of action that can modulate protein interactions in either orthosteric or allosteric ways.
 
We have developed ToRPPIDO to discover disruptors of protein-protein interactions, and ToRNeDO to discover molecular glue-based functional protein degraders using a pre-specified E3 ligase and a neosubstrate of interest.

Our platforms can use canonical small molecule HTS approaches or select from our proprietary genetically encoded peptide and rigidified scaffold libraries of billions of compounds.

OUR PIPELINE

Our internal programs are focused on oncology. We select targets based on oncogene addiction and synthetic lethality.

THE FOUNDING TEAM

Maria Soloveychik

Co-Founder & Chief Executive Officer

Charly Chahwan

Co-Founder & Chief Science Officer

ADVISORY BOARD

Arvind Gupta

Director

Andrew Perlman, MD, PhD

SAB 

Leonard Post, PhD

SAB 

OUR INVESTORS

INCUBATOR AND ACCELERATOR SUPPORT

OPEN POSITIONS

Imagine. Design. Build. Create.

​

Are you an enthusiastic scientist who wants to bring therapies into the clinic? Do you want to use synthetic biology to advance drug discovery? We are always keeping an eye out for new talented members to join the team.

​

RESEARCH ASSISTANT WITH CELL BIOLOGY EXPERTISE (BSC, OR MSC)

​

RESEARCH ASSISTANT WITH BIOCHEMISTRY EXPERTISE (BSC, OR MSC)

​

EXPERIENCED PROTEOMIC SCIENTIST (PHD+)

​

EXPERIENCED MICROBIAL GENETICIST (PHD+)

​

EXPERIENCED BIOCHEMIST (PHD+)

​

EXPERIENCED CELL BIOLOGIST (PHD+)

GET IN TOUCH